Hemosol falls on Hemolink delay

Hemosol (HMSL; TSE:HML) was off $3.42 (44%) to $4.28 on Tuesday. On Monday, the company said it will not restart a U.S. Phase III trial of its Hemolink blood substitute within the next 6 weeks as plan...